The extent of tumor heterogeneity is an emerging theme that researchers are only beginning
to understand. How genetic and epigenetic heterogeneity affects tumor evolution and …

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over
the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a …

The identification of early-stage breast cancer patients at high risk of relapse would allow
tailoring of adjuvant therapy approaches. We assessed whether analysis of circulating tumor …

Precision medicine is a term used to describe individualized treatment that encompasses
the use of new diagnostics and therapeutics, targeted to the needs of a patient based on …

Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and
local responses to tumor growth, thereby altering their RNA profile. We determined the …

Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the
genomic alterations present in tumours and has been used to monitor tumour progression …

Next-generation sequencing of cell-free circulating solid tumor DNA addresses two
challenges in contemporary cancer care. First this method of massively parallel and deep …

The analysis of tumor-derived circulating cell-free DNA opens up new possibilities for
performing liquid biopsies for the assessment of solid tumors. Although its clinical potential …

Background Early indicators of treatment response in metastatic colorectal cancer (mCRC)
could conceivably be used to optimize treatment. We explored early changes in circulating …

Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of
different histological subtypes, treatment sensitivity profiles, and clinical outcomes among …